Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 15/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316097 | 0.91 | ABCG2 (0.55) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL3590103 | 0.81 | ABCG2 (0.67) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16404494 | 0.80 | ABCG2 (0.95) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL3575009 | 0.80 | GRM4 (0.45) | ABCG2MEN1KMT2APDE5AMAPT | |
| SCHEMBL1064726 | 0.78 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16404295 | 0.78 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16404472 | 0.77 | ABCG2 (0.87) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL22201468 | 0.75 | ABCG2 (0.71) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16404355 | 0.74 | ABCG2 (0.78) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL3585832 | 0.74 | ROCK2 (0.64) | ABCG2ABCB1ABCC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | claimed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | claimed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | claimed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ABCG2 3107/4885ABCB1 1785/4885ABCC1 4126/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | ABCG2 1193/4885ABCB1 1129/4885ABCC1 2616/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ABCG2 3107/4885ABCB1 1785/4885ABCC1 4126/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | ABCG2 4736/4885ABCB1 2439/4885ABCC1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.